Molecular signatures and biomarker development for limbic-predominant age-related TDP-43 encephalopathy (LATE)
Blood and spinal fluid biomarkers are emerging to diagnose a common dementia type (LATE) in living patients, potentially improving research and care.
LATE affects approximately one-third of individuals over 80 yet lacks a definitive in-vivo molecular diagnostic; this review summarizes progress in plasma/CSF biomarkers, neuroimaging signatures, and new consensus-based prediction guidelines for LATE-NC. Key gaps remain in discriminating pure LATE from ADNC-mixed disease for clinical trial stratification.
What the study was
- Study design
- Narrative review of LATE biomarker landscape
- Population
- Individuals aged 80+ with TDP-43 proteinopathy (affects ~1/3 of octogenarians)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Acta Neuropathol
Why it surfaced
Timely review of a significantly underdiagnosed age-related disease affecting 1/3 of oldest old. Biomarker pipeline is still early-stage. Useful for aging research program context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.